Schizophrenia News and Research

Latest Schizophrenia News and Research

Oxytocin makes individuals feel calmer and dampens effect on fear receptor in the brain

"My husband of thirty-five years passed away seven years ago, and I lost my daughter in a car accident last year, I honestly could no longer find the energy to smile or laugh," recounts sixty-year-old widow Opal Perry. "My son suggested I try a new hormone being touted to help with symptoms of depression, called oxytocin. After the second day I was driving and caught myself smiling in the mirror. I couldn't believe it. I had to do a double take. I hadn't really smiled in seven years! I thought I would never smile again until now."

23 Dec 2010

Brain regions that 'fire up' due to suppression of automatic behaviour

Research from York University is revealing which regions in the brain "fire up" when we suppress an automatic behaviour such as the urge to look at other people as we enter an elevator.

23 Dec 2010

Ketamine tried on college students in experiments sparks outrage

Department of Psychiatry at Cambridge University designed experiments to investigate treatment methods for schizophrenia. Like schizophrenics who sometimes believe that external objects have become part of their body, injection of ketamine – an anesthetic agent also produces similar feelings. Ketamine is a hallucinogenic drug.

22 Dec 2010

New research sheds light on how neurons make connections with one another

Newly published research led by Professor Z. Josh Huang, Ph.D., of Cold Spring Harbor Laboratory sheds important new light on how neurons in the developing brain make connections with one another.

22 Dec 2010

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Ramius V&O Acquisition LLC, affiliates of Ramius LLC (collectively, "Ramius") and affiliates of Royalty Pharma (together with Ramius and Purchaser, the "Ramius/RP Group") announced today that the Ramius/RP Group is extending its previously announced tender offer to acquire all of the outstanding shares of common stock of Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, until Midnight, January 5, 2011, unless the offer is otherwise extended.

22 Dec 2010

Clue to the blues that come with the flu

Vanderbilt University researchers may have found a clue to the blues that can come with the flu - depression may be triggered by the same mechanisms that enable the immune system to respond to infection.

21 Dec 2010

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Researchers at Vanderbilt University have "engineered" a mouse that can run on a treadmill twice as long as a normal mouse by increasing its supply of acetylcholine, the neurotransmitter essential for muscle contraction.

21 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

MDMA or 'ecstasy' increases feelings of empathy and social connection. These 'empathogenic' effects suggest that MDMA might be useful to enhance the psychotherapy of people who struggle to feel connected to others, as may occur in association with autism, schizophrenia, or antisocial personality disorder.

15 Dec 2010

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

Too often, mental health patients have problems accessing or paying for their prescription drugs under Medicaid. The results — longer hospital stays and more emergency room visits — are hard on patients and costly for the entire health care system, a new study finds.

10 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Alexza Pharmaceuticals, Inc. announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration in December to discuss the Complete Response Letter regarding the Company's New Drug Application for AZ-004 (Staccato loxapine).

8 Dec 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Oxytocin makes individuals feel calmer and dampens effect on fear receptor in the brain

Brain regions that 'fire up' due to suppression of automatic behaviour

Ketamine tried on college students in experiments sparks outrage

New research sheds light on how neurons make connections with one another

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Clue to the blues that come with the flu

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

First genetic test on developing risk of Alzheimer's disease and heart attacks

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Expansion of newborn screening throws some families on a journey of great uncertainty

People suffering psychotic disorders 12 times more likely to commit suicide

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in